Teriparatide is one of the strangest and most successful peptide drugs in modern medicine. It is a fragment of parathyroid hormone — the same hormone that, in chronic excess, dissolves the skeleton — yet given as a daily injection, it does the opposite. It builds new bone, restores trabecular architecture, and cuts vertebral fracture risk by roughly two-thirds. For people with severe osteoporosis facing repeat fractures, teriparatide and its successor abaloparatide remain the only true bone-building peptides on the U.S. market.
This deep dive walks through the discovery, the paradoxical mechanism, the pivotal Fracture Prevention Trial that earned FDA approval in 2002, the rat osteosarcoma scare, and where this anabolic peptide class is heading next.
What Is Teriparatide?
Native parathyroid hormone (PTH) is an 84-amino-acid peptide secreted by the four parathyroid glands. It regulates calcium and phosphate by acting on the kidney, intestine (via vitamin D activation), and bone. Decades of structure-activity work showed that the first 34 amino acids of PTH carry essentially all of the receptor-binding activity. That fragment — recombinant human PTH(1-34) — is teriparatide.
Approval timeline
- 1980s–1990s — Animal and human studies demonstrate that intermittent PTH dosing increases bone mineral density rather than dissolving bone.
- November 2002 — The FDA approves teriparatide (brand name Forteo) from Eli Lilly for the treatment of osteoporosis in postmenopausal women and men at high fracture risk.
- 2004 — Approval extended to glucocorticoid-induced osteoporosis.
- 2017 — Abaloparatide (Tymlos), a synthetic PTHrP analog from Radius Health, is approved for postmenopausal osteoporosis.
- 2019 — The FDA removes the 2-year cumulative use limit black box that had restricted teriparatide since launch, after long-term safety data accumulated.
- 2019 — Romosozumab (Evenity) — a sclerostin-blocking monoclonal antibody, not a peptide — is approved as another anabolic option, though with a cardiovascular black box.
Mechanism of Action
Teriparatide binds the PTH/PTHrP type 1 receptor (PTH1R), a class B G-protein-coupled receptor expressed on osteoblasts and renal tubular cells. Activation triggers Gαs/cAMP/PKA signaling and Gq/PLC/PKC signaling, ultimately increasing osteoblast number and activity.
The paradox is in the dosing schedule:
- Continuous PTH exposure — as occurs in primary hyperparathyroidism — preferentially stimulates osteoclast-driven resorption via RANKL upregulation. The skeleton thins.
- Intermittent PTH exposure — daily subcutaneous injection produces a sharp, brief spike in PTH followed by a long trough. This pulsatile pattern favors osteoblast survival, recruits bone-lining cells back into active osteoblasts, suppresses osteoblast apoptosis through Bcl-2 upregulation, and increases Wnt signaling. Bone formation outpaces resorption — the so-called anabolic window — for the first 6 to 12 months of therapy.
The result, visible on bone biopsy, is increased trabecular thickness, restored connectivity, improved cortical thickness, and even modest periosteal apposition.
Pivotal Clinical Trials
Neer et al., 2001 — The Fracture Prevention Trial (NEJM)
The FPT remains the foundational study. 1,637 postmenopausal women with prior vertebral fractures were randomized to placebo, teriparatide 20 µg/day, or 40 µg/day, for a median 21 months. The trial was stopped early when the rat osteosarcoma signal emerged.
Results were dramatic:
- 65% reduction in new vertebral fractures at the 20 µg dose.
- 53% reduction in non-vertebral fragility fractures.
- Lumbar spine BMD increased 9–13%, femoral neck 3%.
These effect sizes were substantially larger than bisphosphonates achieved on the same endpoint, especially for non-vertebral fractures, and the FPT became the basis for FDA approval in November 2002.
Other key data
- Body et al., 2002 (JCEM) — Comparison with alendronate showed greater BMD gains with teriparatide.
- Saag et al., 2007 (NEJM) — In glucocorticoid-induced osteoporosis, teriparatide outperformed alendronate over 18 months.
- Kendler et al., 2018 VERO trial (Lancet) — In postmenopausal women with severe vertebral osteoporosis, teriparatide produced 56% fewer new vertebral fractures than risedronate over 24 months.
- Miller et al., 2016 ACTIVE trial (JAMA) — Pivotal trial for abaloparatide; showed 86% reduction in vertebral fracture risk vs. placebo over 18 months.
Approved Indications & Use
Teriparatide is FDA-approved for:
- Postmenopausal women with osteoporosis at high risk of fracture (prior fragility fracture, very low T-score, or multiple risk factors).
- Men with primary or hypogonadal osteoporosis at high fracture risk.
- Glucocorticoid-induced osteoporosis in patients at high fracture risk.
Dosing: 20 µg subcutaneously once daily, typically into the thigh or abdomen, using a multidose pen device. Until 2019 the FDA restricted cumulative use to 24 months because of preclinical osteosarcoma findings. That restriction has now been removed, though most clinicians still treat for 18–24 months and follow with an antiresorptive (bisphosphonate or denosumab) to lock in the gains. Without sequential antiresorptive therapy, bone density gradually returns toward baseline.
Teriparatide is reserved for patients with severe disease because of its cost, daily injection, and historical safety concerns. It is not first-line therapy.
Side Effects & Safety
Common adverse effects are mild and tolerable for most patients:
- Transient hypercalcemia (usually within the normal range)
- Mild hypercalciuria
- Orthostatic dizziness, particularly after the first few doses
- Leg cramps
- Nausea, headache
- Injection-site reactions
The osteosarcoma question
The original black box warning flagged an increased risk of osteosarcoma observed in long-term toxicology studies in Fischer 344 rats given near-lifetime, very-high-dose teriparatide. Rats are uniquely susceptible to bone tumor formation under sustained PTH stimulation because of their continuously growing skeletons. Two decades of post-marketing surveillance — including the Forteo Patient Registry — have not shown an increased osteosarcoma rate in humans treated with teriparatide compared with background population rates. On the strength of that evidence, the FDA removed the 24-month lifetime use cap in 2019.
Contraindications still include patients at increased baseline risk of osteosarcoma: Paget's disease of bone, prior skeletal radiation, unexplained elevated alkaline phosphatase, and open epiphyses.
Comparison with other osteoporosis drugs
| Class | Mechanism | Effect |
|---|---|---|
| Bisphosphonates (alendronate, zoledronate) | Inhibit osteoclasts | Antiresorptive — slow bone loss |
| Denosumab (Prolia) | Anti-RANKL antibody | Antiresorptive |
| Teriparatide / abaloparatide | PTH1R agonists | Anabolic — build new bone |
| Romosozumab (Evenity) | Anti-sclerostin antibody | Dual: anabolic + antiresorptive |
Teriparatide is typically chosen when bisphosphonates fail, when fracture risk is exceptionally high, or when bone formation, not just preservation, is the explicit goal.
Connection to Gene Editing & Modern Peptide Therapy
Teriparatide is a vivid case study in why peptide engineering matters. Native PTH(1-84) and PTH(1-34) are nearly identical at the receptor — but the chemistry of pulsatile dosing flips the biological outcome. Today researchers are using that lesson to build longer-acting and orally available bone-anabolic peptides, including weekly PTH analogs already approved in Japan for severe osteoporosis.
Gene therapy and gene editing intersect here too. Sclerostin loss-of-function in humans (sclerosteosis, van Buchem disease) produces dense, fracture-resistant bones — the genetic insight that inspired romosozumab. Researchers are now exploring whether base editing of SOST could safely reduce sclerostin expression for a one-time treatment effect, an idea conceptually related to the base editing approach to replacing GLP-1 injections.
For more on how peptides like teriparatide are designed and stabilized for clinical use, see our explainers on solid-phase peptide synthesis and cyclic peptides for stability.
FAQ
How is teriparatide different from natural PTH?
It is the first 34 amino acids of human PTH — the receptor-binding portion. Native PTH is 84 amino acids. The fragment retains full activity at PTH1R but is easier to manufacture and characterize.
Why does intermittent PTH build bone?
Brief daily spikes preferentially activate osteoblast survival pathways and Wnt signaling, while continuous exposure favors RANKL-driven osteoclast activation. The schedule is the drug.
Is teriparatide safe long-term?
The original 24-month limit was removed in 2019 after post-marketing data showed no increased osteosarcoma risk. Most clinicians still treat for 18–24 months and transition to a bisphosphonate or denosumab.
How does teriparatide compare to abaloparatide?
Both are PTH1R agonists. Abaloparatide is a synthetic analog of PTH-related peptide (PTHrP) with a slightly different binding bias that may produce less hypercalcemia. Head-to-head data favor abaloparatide modestly for non-vertebral fracture reduction.
Do I have to keep taking it forever?
No — and you can't. Teriparatide is a finite anabolic course. Without follow-on antiresorptive therapy, BMD gains erode over the next 12–24 months.
Is romosozumab a peptide?
No. Romosozumab is a humanized monoclonal antibody against sclerostin. It is grouped with anabolic bone therapies but belongs to a different molecular class.
Further Learning
- What Are Peptides? A Complete Guide
- Solid-Phase Peptide Synthesis Explained
- Cyclic Peptides and Therapeutic Stability
This article is for educational purposes and is not medical advice. Anabolic bone therapy carries specific risks and is reserved for patients at high fracture risk. Always consult your physician before starting, changing, or stopping osteoporosis medication.
